Your browser is no longer supported. Please, upgrade your browser.
VRX Valeant Pharmaceuticals International, Inc. daily Stock Chart
Valeant Pharmaceuticals International, Inc.
Index- P/E- EPS (ttm)-4.04 Insider Own2.30% Shs Outstand349.80M Perf Week24.80%
Market Cap5.53B Forward P/E4.15 EPS next Y3.81 Insider Trans-65.18% Shs Float337.69M Perf Month22.20%
Income-1407.30M PEG- EPS next Q0.95 Inst Own66.80% Short Float14.95% Perf Quarter46.98%
Sales9.41B P/S0.59 EPS this Y-714.90% Inst Trans20.07% Short Ratio2.33 Perf Half Y11.27%
Book/sh11.13 P/B1.42 EPS next Y5.80% ROA-3.10% Target Price- Perf Year-28.99%
Cash/sh3.46 P/C4.57 EPS next 5Y-7.26% ROE-34.10% 52W Range8.31 - 32.74 Perf YTD8.82%
Dividend- P/FCF3.44 EPS past 5Y61.43% ROI-1.60% 52W High-51.75% Beta-0.31
Dividend %- Quick Ratio1.00 Sales past 5Y31.90% Gross Margin72.60% 52W Low90.11% ATR0.75
Employees21500 Current Ratio1.30 Sales Q/Q-11.10% Oper. Margin-5.20% RSI (14)73.53 Volatility6.89% 5.16%
OptionableYes Debt/Eq7.33 EPS Q/Q265.40% Profit Margin-15.00% Rel Volume1.75 Prev Close15.50
ShortableYes LT Debt/Eq7.24 EarningsAug 08 BMO Payout- Avg Volume21.62M Price15.80
Recom3.00 SMA2023.44% SMA5035.01% SMA2000.25% Volume37,732,616 Change1.94%
Jun-16-17Initiated Cantor Fitzgerald Overweight $18
May-10-17Reiterated RBC Capital Mkts Sector Perform $18 → $19
Apr-20-17Reiterated JP Morgan Neutral $15 → $10
Mar-23-17Reiterated RBC Capital Mkts Sector Perform $21 → $18
Mar-06-17Reiterated Rodman & Renshaw Neutral $23 → $17
Feb-27-17Reiterated Mizuho Underperform $11 → $9
Feb-14-17Reiterated RBC Capital Mkts Sector Perform $29 → $22
Feb-10-17Reiterated Barclays Equal Weight $34 → $20
Jan-04-17Reiterated Piper Jaffray Underweight $16 → $11
Dec-15-16Downgrade Morgan Stanley Overweight → Equal-Weight $25 → $17
Nov-23-16Downgrade Mizuho Neutral → Underperform $25 → $11
Nov-14-16Reiterated Deutsche Bank Hold $29 → $24
Nov-10-16Reiterated Morgan Stanley Overweight $42 → $25
Nov-10-16Downgrade Rodman & Renshaw Buy → Neutral $81 → $23
Nov-09-16Reiterated RBC Capital Mkts Sector Perform $35 → $29
Oct-14-16Reiterated Deutsche Bank Hold $30 → $29
Oct-12-16Reiterated RBC Capital Mkts Sector Perform $36 → $35
Sep-20-16Resumed Deutsche Bank Hold $30
Aug-17-16Upgrade Morgan Stanley Equal-Weight → Overweight $33 → $42
Aug-15-16Upgrade Mizuho Underperform → Neutral $11 → $25
Jun-24-17 07:05PM  Biden tells Ackman never disrespect memory of his dead son MarketWatch
Jun-23-17 04:02PM  Paulson Times Appointment to Valeant's Board Perfectly Motley Fool
11:54AM  Nvidia Corporation (NVDA) Stock Is Too Hot. Buy This Instead. InvestorPlace
09:06AM  What Bill Miller Thinks about Valeant Now Market Realist
Jun-22-17 04:40PM  Why Barnes & Noble, SunPower, and Valeant Pharmaceuticals Jumped Today Motley Fool +13.30%
12:08PM  Hospitals Rise on Senate Health Bill But Long-Term Prognosis in Question
11:38AM  Does Valeant Pharmaceuticals Intl Inc (VRX) Stock Have a Bull Case? InvestorPlace
08:01AM  Donald Trump Softens Stance on Drug Prices, Sends Biotech Stocks Soaring Motley Fool
07:30AM  Bausch + Lomb Named Most Trusted Contact Lens Solution Brand In Canada For Second Consecutive Year By Brandspark International PR Newswire
07:30AM  Bausch + Lomb Named Most Trusted Contact Lens Solution Brand In Canada For Second Consecutive Year By Brandspark International CNW Group
Jun-21-17 02:11PM  Mizuho Expects Valeant Pharmaceuticals Intl Inc (VRX) Shares to Drift Lower, Pacific Crest Cheers, Inc.s (AMZN) New Prime Wardrobe Service SmarterAnalyst
10:08AM  John Paulson Joining Valeant Pharmaceuticals' Board Isn't a Sufficient Reason to Get Excited Motley Fool
08:15AM  Corporate News Blog - Billionaire Hedge Fund Manager John Paulson Elected to Valeant Pharma's Board Accesswire
Jun-20-17 05:35PM  VRX Investor Alert: Kyros Law is Investigating Legal Claims on Behalf of Valeant Pharmaceuticals Intl (NYSE: VRX) Investors PR Newswire
03:42PM  Why This Billionaire Just Bought Gilead Sciences, Synergy, and Valeant Stock Motley Fool
01:35PM  Is Ford Motor Company (F) Stock Undervalued, Or Cheap for a Reason? InvestorPlace
10:19AM  Company News for June 20, 2017 Zacks
09:52AM  Yes, Valeant is Rising But
08:00AM  Today's Research Reports on Stocks to Watch: Clovis Oncology and Valeant Pharmaceuticals Accesswire
12:37AM  [$$] Hedge-Fund Manager John Paulson Joins Valeant Board The Wall Street Journal
Jun-19-17 06:31PM  John Paulson Joins Valeant's Board During Trying Transition +6.40%
06:00PM  Valeant Appoints Arthur J. Shannon As Senior Vice President, Head Of Investor Relations And Communications PR Newswire
05:37PM  Gabelli's Jonas Doesn't Expect Much Change at Valeant Bloomberg Video
04:32PM  Why Valeant Pharmaceuticals, Rite Aid, and Novadaq Technologies Jumped Today Motley Fool
03:33PM  Why John Paulson Can't Rescue Valeant's Stock Investopedia
01:47PM  Valeant Pharmaceuticals Intl Inc (VRX) Stock Isnt Healed by Paulsons Presence InvestorPlace
01:14PM  John Paulson Won't Save Valeant Bloomberg
01:04PM  Valeant: Accentuate the Negative?
01:04PM  Billionaire John Paulson Wants You to Buy Valeant -- Here's What the Chart Says
10:41AM  John Paulson joins Valeant's board after his firm took a ... CNBC Videos
10:28AM  Billionaire Hedge Funder John Paulson Joins Valeant Board Investopedia
10:12AM  Billionaire investor Paulson joins Valeant board, shares jump Reuters
09:59AM  Can John Paulson Revive Valeant?
09:53AM  James Flynn Plays Two Key Biotech Stocks: Valeant Pharmaceuticals Intl Inc (VRX), Gilead Sciences, Inc. (GILD) SmarterAnalyst
09:29AM  Stocks to Watch: Apple, Amazon, Rice Energy, Valeant The Wall Street Journal
09:27AM  Top 3 Companies Owned by Valeant (VRX) Investopedia
09:26AM  Stocks edge higher and Trump meets with Bezos, Cook and other tech execs Yahoo Finance
09:22AM  [$$] Hedge-Fund Manager John Paulson Joins Valeant Board The Wall Street Journal
08:34AM  Early movers: WFM, COST, VRX, KR & more CNBC
08:28AM  John Paulson joins Valeant's board after his firm took a nearly $2 billion hit on its stock CNBC
08:21AM  Valeant Stock Jumps After John Paulson Named to Board
07:45AM  Valeant's stock surges after largest shareholder John Paulson elected to board MarketWatch
07:39AM  Valeant's largest shareholder John Paulson joins board Reuters
07:22AM  Valeant adds shareholder John Paulson to board Reuters
07:15AM  Billionaire John Paulson Joins Valeants Board of Directors Bloomberg
07:00AM  John Paulson Joins Valeant Board Of Directors PR Newswire
Jun-16-17 05:28PM  Investing legend and Amazon bull Bill Miller likes Whole Foods deal, plus Valeant and bitcoin CNBC
10:54AM  Valeant: Stop Looking in the Rearview Mirror!
09:10AM  Cantors First Take: Bullish on Valeant Pharmaceuticals Intl Inc (VRX), Sidelined on Endo International (ENDP) SmarterAnalyst
08:30AM  Morning Movers: Celgene Gains, Nike Drops, Valeant Rises
Jun-15-17 03:38PM  Valeant Pharmaceuticals Intl Inc (VRX) Stock Is a Great Speculative Value InvestorPlace
Jun-14-17 07:07AM  Valeant (VRX) Down 4% Since Earnings Report: Can It Rebound? Zacks
Jun-13-17 09:50AM  Tesla Inc (TSLA) Stock May Face a Reckoning InvestorPlace
Jun-12-17 04:49PM  Valeant Inks Deal to Divest iNova Pharmaceuticals for $930M Zacks
03:02PM  Valeant: Accentuate the Positive?
02:08PM  Trader Who Called Valeant Short Predicts Nvidia Decline Investopedia
12:40PM  Billionaire Israel Izzy Englander Bets on Three Biotech Stocks: Valeant Pharmaceuticals Intl Inc (VRX), Gilead Sciences, Inc. (GILD), Synergy Pharmaceuticals Inc (SGYP) SmarterAnalyst
11:46AM  It's Happening Again: Valeant's Stock Jumped for a Silly Reason Motley Fool
Jun-10-17 12:03PM  What Valeant Pharmaceuticals' Latest Sale Means (and Doesn't Mean) for Investors Motley Fool
Jun-09-17 04:34PM  Nvidia stock drops 8 percent on a short-sellers tweet American City Business Journals -5.58%
02:47PM  Valeant: What It Wants You to Ignore?
10:00AM  What Valeant Pharmaceuticals' $930 Million Deal Means Motley Fool
09:08AM  Canaccord Lifts Price Target on Valeant Pharmaceuticals Intl Inc (VRX), Cuts Endo International plc SmarterAnalyst
08:00AM  Today's Research Reports on Stocks to Watch: Endo International and Valeant Pharmaceuticals Accesswire
07:57AM  Instant Analysis: Valeant to Sell iNova Unit for $930 Million Motley Fool
01:21AM  [$$] Valeant to Sell iNova Unit for $930 Million The Wall Street Journal
Jun-08-17 04:32PM  Why Valeant Pharmaceuticals, Hudbay Minerals, and Comtech Telecommunications Jumped Today Motley Fool +8.96%
04:30PM  Valeant's Latest Divestiture Seems to Please Investors But Its Massive Debt Still Hovers
04:24PM  Why Valeant Pharmaceuticals Intl. Inc. Jumped Higher Today Motley Fool
04:14PM  CANADA STOCKS-TSX ends higher as Valeant bounces, banks gain Reuters
02:51PM  Stocks Deflate as Wall Street Digests Fallout of Comey Testimony
01:37PM  Valeant Still Has A Big Debt Problem Investopedia
01:04PM  UPDATE: Valeant Pharmaceuticals: Almost There?
12:54PM  Valeant Pharmaceuticals: Bigger is Better
11:27AM  Dont Buy the Valeant Pharmaceuticals Intl Inc (VRX) Stock Hype InvestorPlace
10:16AM  [$$] Valeant to Sell iNova Unit for $930 Million The Wall Street Journal
09:28AM  Stocks to Watch: Nordstrom, Ford, Yahoo, Nvidia, Valeant The Wall Street Journal
09:19AM  Valeant to Sell iNova Unit in Latest Bid to Pay Off Long-Term Debt
08:40AM  Valeant to sell iNova unit for $930 mln to repay debt Reuters
08:31AM  Morning Movers: Valeant Gains on iNova Sale, Urban Outfitters Slumps
08:10AM  UPDATE: Valeant shares jump 5% premarket on news of sale of iNova Pharmaceuticals for $930 million MarketWatch
08:07AM  Valeant's sale of iNova is debt neutral, says Evercore analyst MarketWatch
07:48AM  Early movers: BABA, SJM, P, URBN, VRX, YHOO, AMZN & more CNBC
07:11AM  Valeant to sell its iNova Pharmaceuticals business for $930 mln Reuters
07:00AM  Valeant Announces Sale of iNova Pharmaceuticals for $930 Million PR Newswire
Jun-07-17 04:42PM  The Not-So-Subtle Reason Behind Valeant Pharmaceuticals' 30% Rise in May Motley Fool
02:29PM  Tiger Cub Rob Citrone Is Bullish on Valeant Pharmaceuticals Intl Inc (VRX), Advanced Micro Devices, Inc (AMD), Slashes, Inc. (AMZN) SmarterAnalyst
Jun-06-17 12:16PM  Perrigo: As the Revolving Door Spins
11:38AM  Don't Buy Valeant's Latest Asset-Sale Hype Bloomberg
09:46AM  Valeant surges 4% on report that it's in talks to sell eye surgical products business MarketWatch
09:43AM  Valeant in talks to sell eye-surgery assets to Carl Zeiss - Bbg Reuters
09:19AM  Valeant in talks to sell eye surgical products business - Bbg Reuters
07:01AM  Valeant Is in Talks to Sell Eye-Surgery Assets to Carl Zeiss Bloomberg
Jun-05-17 02:36PM  Mallinckrodt stock tumbles after new Citron Research report targets $40,000-a-vial drug MarketWatch
11:58AM  Citron Takes Aim at Mallinckrodt, Blasts Acthar Gel Medication
09:51AM  Investors Are Fleeing John Paulson's Once Hot Hedge Fund Benzinga
08:45AM  Safirstein Metcalf LLP and HGT Law Remind Investors About Update on Valeant Pharmaceuticals International Inc. Class Action - VRX GlobeNewswire
May-31-17 05:00PM  Valeant Pharmaceuticals To Present At Financial Industry Conferences PR Newswire
12:31PM  We just witnessed 2 perfect examples of Wall Street billionaires spinning major fails Business Insider
11:00AM  EYEG: Pipeline Progress Continues, Includes First Valeant Ocular Surgery Development Milestone Zacks Small Cap Research
Valeant Pharmaceuticals International, Inc. operates as a pharmaceutical and medical device company worldwide. It operates in three segments: Bausch + Lomb/International, Branded Rx, and U.S. Diversified Products. The company offers Lotemax gel for the treatment of inflammation and pain following ocular surgery; Ocuvite, a lutein eye vitamin and mineral supplement; PreserVision, an antioxidant eye vitamin and mineral supplement; ReNu Multiplus products; Biotrue multi-purpose solution for healthy contact lens wear; Artelac to treat dry eyes; Boston, a cleansing solution for gas permeable contact lenses; and Bedoyecta, a vitamin B complex. It also provides SofLens daily disposable contact lenses; ophthalmic surgical products; PureVision, a silicone hydrogel; Biotrue ONEday daily disposable contact lenses; Bausch + Lomb Ultra, a silicone hydrogel replacement contact lens; and medical device systems. In addition, the company offers Xifaxan for the treatment of irritable bowel syndrome; Provenge for the treatment of prostate cancer; Uceris to get ulcerative colitis under control; Arestin, a subgingival sustained-release antibiotic; Jublia for the treatment of onychomycosis; Solodyn for the treatment of acne; Elidel to treat skin conditions; and Glumetza tablets to enhance glycemic control. Further, it provides Wellbutrin XL for the treatment of major depressive disorder; Isuprel injections; Xenazine for the treatment of chorea; Nitropress for the reduction of blood pressure of patients in hypertensive crises; Cuprimine to treat Wilson's disease; Zegerid to treat certain stomach and esophagus problems; Tobramycin and Dexamethasone ophthalmic suspension for steroid responsive inflammatory ocular conditions; and Latanoprost medicines to treat a type of glaucoma. The company was formerly known as Biovail Corporation and changed its name to Valeant Pharmaceuticals International, Inc. in September 2010. The company was founded in 1983 and is headquartered in Laval, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DE SCHUTTER RICHARD UDirectorMay 11Buy13.9020,000278,00070,572May 15 05:19 PM
DE SCHUTTER RICHARD UDirectorMar 15Buy10.8010,000108,00025,190Mar 16 05:12 PM
Herendeen PaulEVP and CFOMar 14Buy10.7224,000257,280174,000Mar 16 05:04 PM
ValueAct Holdings, L.P.DirectorMar 14Buy10.823,000,00032,465,00016,937,431Mar 16 04:31 PM
Pershing Square Capital ManageDirectorMar 13Sale11.0018,114,432199,258,7520Mar 14 04:14 PM
Ross Thomas W. Sr.DirectorDec 14Buy14.735,00073,65026,822Dec 16 04:19 PM
Pershing Square Capital ManageDirectorDec 12Sale14.853,476,69051,628,84718,114,432Dec 13 04:14 PM
KARABELAS ARGERIS NDirectorAug 11Buy24.654,00098,60020,726Aug 12 04:37 PM